From 1 to 4 March 2023, after 3 years, the first post-pandemic ECCO Congress took place in Copenhagen, Denmark. Among the talks given by the world’s top IBD specialists, our colleague Larissa Brosi, from the BÜHLMANN development team, presented a poster comparing Quantum Blue® Infliximab and Adalimumab trough levels measured in serum, EDTA whole blood, and capillary blood. In addition, she demonstrated that icteric, lipemic and haemolytic blood, common problems with blood samples, showed no systemic interference.
P149 – Novel capillary blood point-of-care test for adalimumab and infliximab trough levels: Effects of abnormal blood conditions on the test result
The pandemic showed the importance of having tests available as close as possible to the patients. Rapid testing for therapeutic drug monitoring (TDM) and fecal calprotectin on the Quantum Blue® Reader, performed in the laboratory, at the doctor’s office, or even at home thanks to IBDoc®, the BÜHLMANN IBD test portfolio aims to improve quality of life of all IBD patients.
BÜHLMANN is proud to be part of the IBD community and supports patients and doctors with the best available assays.
We also presented our new IBDoc® tutorial video.